New CHEK2 Variant and Breast Cancer Risk in French Canadian Women
Author Information
Author(s): David J. Novak, Long Qi Chen, Parviz Ghadirian, Nancy Hamel, Phil Zhang, Vanessa Rossiny, Guy Cardinal, André Robidoux, Patricia N. Tonin, Francois Rousseau, Steven A. Narod, William D. Foulkes
Primary Institution: McGill University
Hypothesis
Does the novel CHEK2 variant R406H contribute to breast cancer risk in French Canadian women?
Conclusion
The novel CHEK2 missense variant R406H is unlikely to contribute to breast cancer risk in French Canadian women.
Supporting Evidence
- The study sequenced the CHEK2 gene in a panel of 25 affected women and 25 healthy controls.
- Two variants were identified, including a novel missense variant R406H.
- No significant difference in allele distribution between breast cancer patients and healthy controls was observed.
Takeaway
Scientists looked for a new gene change that might cause breast cancer in French Canadian women, but they found it doesn't seem to make a difference.
Methodology
The study sequenced the CHEK2 gene in 25 breast cancer patients and 25 healthy controls, then screened for the novel variant in larger groups.
Potential Biases
Potential selection bias in the recruitment of participants may affect the generalizability of the findings.
Limitations
The study's sample size may limit the ability to detect rare variants and their associations with breast cancer risk.
Participant Demographics
Participants included 25 affected French Canadian women and 25 healthy controls, with additional groups for screening.
Statistical Information
P-Value
0.73
Statistical Significance
p = 0.73
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website